Shattuck Labs (STTK) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

STTK Shattuck Labs

Watchlist

1.140
-0.060-5.00%

Close Dec 13 16:00 ET

54.42MMarket Cap-0.75P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shattuck Labs Announces Participation in Upcoming December Conferences
GlobeNewswireNov 25 07:00 ET
Shattuck Labs Focuses on Promising Antibody Development
TipRanksNov 18 22:53 ET
TD Cowen Maintains Shattuck Labs(STTK.US) With Buy Rating
Moomoo NewsNov 14 19:31 ET · Ratings
Shattuck Labs Analyst Ratings
BenzingaNov 14 13:46 ET · Ratings
Express News | Shattuck Labs Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
BenzingaNov 14 12:30 ET
H.C. Wainwright Maintains Shattuck Labs(STTK.US) With Hold Rating
Moomoo NewsNov 14 09:33 ET · Ratings

Comments

Johnny Mnemonic

Dec 4 16:45

holding at $1

Johnny Mnemonic

Oct 2 08:47

quit selling u stupid fks

Jaguar8

Oct 1 05:50

NEWS

$Shattuck Labs (STTK.US)$
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...

Trytosaveabit

Jun 26 16:05

Insider buy

$Shattuck Labs (STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.

Trytosaveabit

Jun 14 05:34

Update

$Shattuck Labs (STTK.US)$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...

Heat List

Overall

No Data